This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BD (BDX) to Expand Base in Pharmacy Automation With New Buyout
by Zacks Equity Research
BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.
Here's Why Investors Should Retain Globus Medical (GMED) Now
by Zacks Equity Research
Globus Medical's (GMED) strong international growth and meaningful product launches raise investors' optimism.
Neogen (NEOG) to Offer New Biosecurity Solution in Canada
by Zacks Equity Research
Neogen's (NEOG) newest addition to the biosecurity portfolio is anticipated to curb the spread of diseases like COVID-19 and avian influenza.
Anthem (ANTM) Up 27% in a Year: Can It Retain the Momentum?
by Zacks Equity Research
Anthem (ANTM) is well-poised for growth on sustained top-line improvement, membership increases in Government business and sturdy financial position.
Here's Why You Should Retain AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
HealthEquity (HQY) Q1 Earnings Lag Estimates, FY23 View Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust segmental revenues, in the first quarter of fiscal 2023.
Here's Why You Should Hold on to Avanos (AVNS) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.
Here's Why You Should Retain Baxter (BAX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.
Here's Why You Should Retain ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies. However, limited commercial expertise is a woe.
Cardinal Health (CAH) to Extend Warehouse Footing With New Center
by Zacks Equity Research
Cardinal Health's (CAH) new distribution center to support the company's at-Home Solutions business.
BD's (BDX) Latest Product to Transform Research Outcome
by Zacks Equity Research
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting as well as provide answers to previously unthinkable questions.
If You Invested $1000 in AMN Healthcare Services 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Surging Earnings Estimates Signal Upside for AMN Healthcare (AMN) Stock
by Zacks Equity Research
AMN Healthcare (AMN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
LabCorp (LH) to Enhance Access to OmniSeq INSIGHT via New Program
by Zacks Equity Research
LabCorp's (LH) new sponsored lung cancer program will expand access to comprehensive genomic testing for NSCLC patients to guide informed treatment decisions.
Cooper Companies (COO) Q2 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal second-quarter earnings reflect solid segmental performance.
Phibro (PAHC) Business Hurt by Macro Issues, FX Fluctuations
by Zacks Equity Research
The increase in raw material costs and freight costs continues to pose challenges for Phibro (PAHC).
Accuray's (ARAY) New Tie-Up to Augment Treatment Planning
by Zacks Equity Research
Accuray (ARAY) partners with Limbus AI to enhance the treatment planning process and patient care.
Leverage Relative Price Strength With These 5 Top Stocks
by Nilanjan Choudhury
Kronos Worldwide (KRO), Ulta Beauty (ULTA), AMN Healthcare Services (AMN), Marathon Petroleum (MPC) and Sanderson Farms (SAFM) are five stocks with explosive relative price strength.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell's (OMCL) better-than-expected results and new launches.
Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY23 View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both of its segments.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
DexCom (DXCM) to Boost Diabetes Management With New Coverage
by Zacks Equity Research
DexCom's (DXCM) G6 CGM System gets public coverage through Prince Edward Island's Diabetes Glucose Sensor Program, which can aid in effective diabetes management.
Abbott (ABT) Receives FDA Nod for FreeStyle Libre 3 System
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 3 system offers greater accuracy and easier application compared with other CGMs.
Here's Why Investors Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and strong performance across several geographies.